This organoid precisely mimics actual liver function by three-dimensionally recreating the microenvironment of human and rodent liver cells. It is gaining attention as a platform to replace existing animal testing, as it can evaluate drug metabolism, transport, and hepatotoxicity. This technology is receiving even greater recognition, especially after the FDA announced its policy allowing NAMs-based approaches. A key feature is its ability to maximize analysis efficiency and precision when combined with AI-based predictive models. This model is currently offered by Labcorp as an outsourced testing platform for pharmaceutical companies. It is also expected to have potential applications in personalized drug response testing for individual patients. It is evaluated as having improved reliability due to its higher physiological similarity compared to traditional 2D liver cell assays. Research is underway to expand its application to other organs such as the heart, lungs, and kidneys. This is expected to be a representative case symbolizing the rapid growth of the organoid-based non-clinical market.